Abstract 4740
Background
Primary cerebral lymphoma (PCL) is a rare malignancy representing less than 1.5% of brain tumors. Given the lack of studies in the literature that describe PCL, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to investigate PCL’s prognostic factors, incidence and survival rates.
Methods
We conducted a retrospective population-based cohort study using SEER database from 1983-2014. Patients with primary lymphoma as their only primary malignancy analyzed. Patients who were diagnosed by autopsy, had no active follow up in the registry and with unknown Ann Arbor Staging, or radiology status were excluded. We also calculated the frequencies and the average annual age-adjusted rate (AAR) of PCL patients between 2000 and 2015. Uni- and multivariable accelerated failure time regression were used to identify possible prognostic factors affecting the patient’s survival.
Results
We identified 1,196 PCL cases, with an average age of diagnosis 56.71 ± 17.28 years and 59.9% were males. Diffuse B-cell lymphoma was the most prevalent sub-type (61.3%). AAR was 0.14 per 100,000. These rates were higher in males, Asian or Pacific Islander and increasing with age. PCL-specific 1-year, 2-year, and 5-year survival rates were 89.6%, 84.4%, and 67%, respectively. Increased age (HR: 1.02, 95%CI=1.01–1.03, P < 0.001) and recent diagnosis after 2002 (HR: 2.42, CI = 1.46–3.42, P < 0.001) were significantly associated with shorter survival, while having a PCL in the temporal lobe (HR: 0.62, 95%CI=0.40–0.98, P = 0.040), or parietal lobe (HR: 0.63, 95%CI=0.42–0.94, P = 0.024) as compared to the other sites, and receiving radiation (HR: 0.37, 95% CI = 0.15–0.92, P = 0.033) or chemotherapy (HR: 0.64, 95%CI=0.50–0.83, P = 0.001) were associated with improved survival.
Conclusions
This is the first report to shed light on PCL’s incidence, survival rate, and prognostic factors. As a result, it will provide physicians and researchers with insights about this rare malignancy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sherief Ghozy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract